This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Read More
Category: News
Going live with the “ALS Center” app
We are pleased to inform you that our new “ALS Center” app will go live on 02.04.2026. The ALS Center app was developed to give doctors and staff at ALS outpatient clinics quick and clear access to the most important progress data of their ALS patients. The app displays the following information, among other things:…
Update of the SMA app: new functions and improved user-friendliness
New functions have been added to the SMA app and its user-friendliness has been optimized. The latest update to version 2.0.7 is now available free of charge from the Apple App Store and Google Play. The most important new features of the current version are briefly presented below. Illustration of the individual course of SMA…
Launch event for the MANAGE-SMA study in Berlin
The kick-off event for the MANAGE-SMA study will take place in Berlin on March 23 and 24, 2026. The MANAGE-SMA study is the focus of the event. Treatment experience, treatment satisfaction and motor function in adult patients with 5q-SMA will be investigated. The therapies nusinersen 12 mg, risdiplam and the higher-dose nusinersen therapy (50/28 mg)…
ALS & SMA service chat on the APST website
We are very pleased to introduce a new feature on the APST website: our ALS & SMA Service Chat. With this new chatbot, you can get quick support with questions about The ALS & SMA service chat helps you to find your way around our website even more easily, to discover suitable information more quickly…
ALS network symposium with APST in Berlin on April 16, 2026
The ALS Network Symposium will take place in Berlin from Wednesday, April 15 to Friday, April 17. Traditionally, the symposium begins on Wednesday evening with an informal get-together. On Thursday, the following topics are planned by APST and Charité – Universitätsmedizin Berlin: – the ALS phenotype biomarker registry with a focus on ALS-OPM classification, NfL…
DMC in ALS
During the course of their disease, around 90% of patients with ALS develop speech or swallowing difficulties – so-called bulbar symptoms. Around a third of all patients already show bulbar symptoms at the onset of ALS. Dextromethorphan/quinidine (DMC) has established itself as an off-label treatment option to alleviate these symptoms in ALS. In a patient…
Together since 2011 – 15 years of APST
2026 is a special year for us: APST is celebrating its 15th anniversary. Since our founding, we have stood for reliable support, dedicated research, and digital services for people with ALS, SMA, and other motor neuron diseases. Thank you for your trust, your loyalty, and the many shared experiences over the past years. We look…
The ALS app at the international ALS symposium in San Diego
On December 4, 2025, the ALS app will be presented at the“ALS App Europe Initiative Meeting” at the International Symposium on ALS/MND in San Diego (USA). The meeting brings together European and American ALS centers, researchers and patient initiatives. You can find out more about the program here: https://symposium.mndassociation.org/programme/satellite-meetings/ The “ALS App Europe Initiative” meeting…
Which ALS outpatient clinics use the OPM classification?
Following our last newsletter on the introduction of the OPM classification in the ALS app, we have received numerous queries: Which ALS outpatient clinics in Germany already use the OPM classification as part of the “NfL study in ALS”? We are pleased to be able to provide you with a transparent overview. ALS outpatient clinics…
The new ALS-OPM classification is now in the ALS app.
We are pleased to introduce an important new feature in the ALS app today: The new OPM classification is now live! The OPM classification has been available in the current app version 5.10.4 for iOS (Apple) and Android (Google) since yesterday. What does the OPM classification mean? The phenotype of ALS – i.e. the individual…